NeuBase Therapeutics (NASDAQ:NBSE) was the target of a significant decrease in short interest during the month of September. As of September 30th, there was short interest totalling 133,700 shares, a decrease of 40.2% from the August 30th total of 223,400 shares. Based on an average daily volume of 159,300 shares, the days-to-cover ratio is currently 0.8 days. Approximately 1.2% of the company’s shares are short sold.
A number of research firms recently commented on NBSE. BTIG Research began coverage on NeuBase Therapeutics in a report on Tuesday, September 24th. They issued a “buy” rating and a $15.00 price objective for the company. ValuEngine downgraded NeuBase Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 5th.
Shares of NeuBase Therapeutics stock traded up $0.22 during trading hours on Friday, hitting $4.72. The company’s stock had a trading volume of 36,691 shares, compared to its average volume of 86,837. NeuBase Therapeutics has a 12 month low of $1.60 and a 12 month high of $6.95.
About NeuBase Therapeutics
NeuBase Therapeutics, Inc, a biotechnology company, engages in the development of various antisense therapies to address genetic diseases in the United States. The company offers gene silencing therapies, including the proprietary PATrOL platform, a peptide-nucleic acid antisense oligonucleotide for genetic diseases caused by mutant proteins, including the Huntington's disease and myotonic dystrophy, as well as various other genetic disorders.
Further Reading: What is the formula for the cash asset ratio?
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.